Rebecca Hluhanich

Impact of Primary Elvitegravir Resistance-Associated Mutations in HIV-1 Integrase on Drug Susceptibility and Viral Replication Fitness

Michael E. Abram, Rebecca Hluhanich, Derrick Goodman et al. · Antimicrobial Agents and Chemotherapy · 2013 · 110 citations · Full text

Viral Replication Fitness, Hiv-1 Integrase, Drug Susceptibility +15

In vitro resistance selections using elvitegravir, raltegravir, and two metabolites of elvitegravir M1 and M4

Nicolas Margot, Rebecca Hluhanich, G.S. Jones et al. · Antiviral Research · 2011 · 66 citations

Medicine, Antiviral Drug Development, Antiviral Therapy +8

Triazole derivatives as non-nucleoside inhibitors of HIV-1 reverse transcriptase—Structure–activity relationships and crystallographic analysis

Thorsten Kirschberg, M. Balakrishnan, Wei Huang et al. · Bioorganic & Medicinal Chemistry Letters · 2007 · 39 citations

Biochemistry, Medicine, Non-nucleoside Inhibitors +8

The Combined Anti-HIV-1 Activities of Emtricitabine and Tenofovir plus the Integrase Inhibitor Elvitegravir or Raltegravir Show High Levels of Synergy<i>In Vitro</i>

Rima Kulkarni, Rebecca Hluhanich, Damian M. McColl et al. · Antimicrobial Agents and Chemotherapy · 2014 · 23 citations · Full text